olaparib

collagen type XI alpha 2 chain ; Homo sapiens







115 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
51 31101118 Olaparib and ionizing radiation trigger a cooperative DNA-damage repair response that is impaired by depletion of the VRK1 chromatin kinase. 2019 May 17 1
52 31296812 [Hereditary Breast and Ovarian Cancer Syndrome]. 2019 Jul 1
53 28146604 The clinically used PARP inhibitor olaparib improves organ function, suppresses inflammatory responses and accelerates wound healing in a murine model of third-degree burn injury. 2018 Jan 1
54 29382645 First PARP Inhibitor Ok'd for Breast Cancer. 2018 Mar 1
55 29465803 Olaparib is effective in combination with, and as maintenance therapy after, first-line endocrine therapy in prostate cancer cells. 2018 Apr 1
56 29582690 Olaparib for the treatment of breast cancer. 2018 Jun 1
57 29748182 A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening. 2018 Sep 1 1
58 29898896 Nuclear PTEN Localization Contributes to DNA Damage Response in Endometrial Adenocarcinoma and Could Have a Diagnostic Benefit for Therapeutic Management of the Disease. 2018 Sep 1
59 29983873 Simultaneous delivery of olaparib and carboplatin in PEGylated liposomes imparts this drug combination hypersensitivity and selectivity for breast tumor cells. 2018 Jun 19 2
60 30057890 Combined ATR and DNA-PK Inhibition Radiosensitizes Tumor Cells Independently of Their p53 Status. 2018 1
61 30084837 Final Report of a Phase I Trial of Olaparib with Cetuximab and Radiation for Heavy Smoker Patients with Locally Advanced Head and Neck Cancer. 2018 Oct 15 1
62 30232143 Androgen Receptor Inhibitor Enhances the Antitumor Effect of PARP Inhibitor in Breast Cancer Cells by Modulating DNA Damage Response. 2018 Dec 1
63 30333000 Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report. 2018 Oct 17 1
64 30353044 Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes. 2018 Nov 1
65 30555227 Intraperitoneal delivery of NanoOlaparib for disseminated late-stage cancer treatment. 2018 1
66 28138868 Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer. 2017 Mar 1
67 28323658 Changing face of metastatic prostate cancer: the law of diminishing returns holds true. 2017 May 1
68 28395540 Olaparib for the treatment of breast cancer. 2017 Jun 1
69 28450425 Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. 2017 Sep 1
70 28450426 Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors. 2017 Sep 1
71 28454085 Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer. 2017 Jul 18 2
72 28512243 Plk1 Phosphorylation of Mre11 Antagonizes the DNA Damage Response. 2017 Jun 15 1
73 28916476 Pharmacologic ascorbate induces neuroblastoma cell death by hydrogen peroxide mediated DNA damage and reduction in cancer cell glycolysis. 2017 Dec 1
74 29290761 The OlympiAD trial: who won the gold? 2017 1
75 26899229 Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer. 2016 1
76 26909613 Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer. 2016 Mar 15 2
77 26934368 Radiosensitization by PARP Inhibition in DNA Repair Proficient and Deficient Tumor Cells: Proliferative Recovery in Senescent Cells. 2016 Mar 1
78 26961146 Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety. 2016 Jun 1
79 26961668 Recent Patents for Homologous Recombination Deficiency Assays Among Women with Ovarian Cancer. 2016 1
80 27065456 Homologous recombination deficiency and ovarian cancer. 2016 Jun 1
81 27345073 The integration of BRCA testing into oncology clinics. 2016 Jun 23 1
82 27617661 Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. 2016 Nov 1
83 27708239 FOXC1 identifies basal-like breast cancer in a hereditary breast cancer cohort. 2016 Nov 15 1
84 27924011 Roles for APRIN (PDS5B) in homologous recombination and in ovarian cancer prediction. 2016 Dec 15 1
85 25404465 PARP inhibitor, olaparib ameliorates acute lung and kidney injury upon intratracheal administration of LPS in mice. 2015 Feb 1
86 25583815 Olaparib effective in four advanced cancers. 2015 Jan 1
87 25634209 Interaction of BARD1 and HP1 Is Required for BRCA1 Retention at Sites of DNA Damage. 2015 Apr 1 1
88 25758301 [Should knowledge of BRCA1 status impact the choice of chemotherapy in metastatic breast cancer: a review]. 2015 Mar 1
89 25975349 The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells. 2015 Jul 6
90 25981132 Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells. 2015 Sep 2
91 26095524 XI-006 induces potent p53-independent apoptosis in Ewing sarcoma. 2015 Jun 22 1
92 26097887 A quasi-quantitative dual multiplexed immunoblot method to simultaneously analyze ATM and H2AX Phosphorylation in human peripheral blood mononuclear cells. 2015 2
93 26303225 PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis. 2015 Oct 1
94 26310895 Quinazolinedione SIRT6 inhibitors sensitize cancer cells to chemotherapeutics. 2015 Sep 18 1
95 26312527 Replication-induced DNA damage after PARP inhibition causes G2 delay, and cell line-dependent apoptosis, necrosis and multinucleation. 2015 1
96 26510020 DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. 2015 Oct 29 2
97 24534203 Combination of AZD2281 (Olaparib) and GX15-070 (Obatoclax) results in synergistic antitumor activities in preclinical models of pancreatic cancer. 2014 Jun 28 1
98 24632590 Linking off-target kinase pharmacology to the differential cellular effects observed among PARP inhibitors. 2014 May 30 1
99 24748377 Pathway-specific engineered mouse allograft models functionally recapitulate human serous epithelial ovarian cancer. 2014 1
100 24784564 Indoleamine 2,3-dioxygenase mediates immune-independent human tumor cell resistance to olaparib, gamma radiation, and cisplatin. 2014 May 15 1